When will Repatha have a generic version?
Repatha (evolocumab) is a biologic (an antibody), so it does not typically get a traditional “small-molecule generic.” Instead, the closest equivalent would be a biosimilar. Whether one is available depends on patent and exclusivity timelines, and on regulatory approvals.
To check the latest status and the timing of patent expiry (and related exclusivity), use DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
Is there already a biosimilar version of Repatha?
Search for “evolocumab biosimilar” rather than “Repatha generic.” If a biosimilar is approved and launched, you may see different brand names, but it would still be tied to the same active ingredient (evolocumab) at the biosimilar level. Patent and market coverage can delay launches even after regulatory approval.
How long do Repatha patents/exclusivity usually block cheaper versions?
Repatha’s availability of lower-cost alternatives usually depends on when key patents and biologic exclusivity protections expire, plus whether companies successfully challenge those patents in court. DrugPatentWatch tracks these developments and is a practical starting point for current timelines: https://www.drugpatentwatch.com/
What’s the difference between “generic” and “biosimilar” for Repatha?
Because Repatha is a biologic:
- A true “generic” equivalent usually applies to standard chemical drugs, not antibodies.
- A “biosimilar” is the biologic equivalent that can be substituted under specific rules and sometimes only after guideline/insurer requirements are met.
If no biosimilar is available yet, what alternatives do patients use?
When Repatha can’t be replaced with a biosimilar, patients often switch within the same cholesterol-lowering class or to a different mechanism if clinically appropriate (for example, other PCSK9-targeting options or other lipid-lowering therapies). Insurance formularies often drive these choices before biosimilars arrive.
---
If you tell me your country (US, UK, Canada, etc.) and whether you mean “generic” in the strict sense or “any cheaper substitute,” I can tailor the answer to what regulators and insurers there typically allow.